Chiome BioscienceChiome Bioscience Inc.4583東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP
It lost about ¥165 for every ¥100 of sales at the operating level. Revenue changed -24.0% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -63.3% | —× | — |
| 2022 | — | —× | -54.6% | —× | — |
| 2023 | — | —× | -61.5% | —× | — |
| 2024 | — | —× | -48.4% | —× | — |
| 2025 | — | —× | -46.8% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 713 | 631 | 682 | 781 | 593 |
| Cost of revenue | 290 | 282 | 284 | 348 | 238 |
| Gross profit | 422 | 349 | 399 | 433 | 356 |
| SG&A | 1,757 | 1,608 | 1,604 | 1,464 | 1,335 |
| Operating income | -1,334 | -1,259 | -1,205 | -1,031 | -980 |
| Pretax income | -1,466 | -1,238 | -1,215 | -1,018 | -980 |
| Income tax | 13 | 5 | 5 | 3 | 3 |
| Net income attributable to owners | -1,480 | -1,243 | -1,220 | -1,021 | -983 |
| Operating margin | -187.2% | -199.5% | -176.6% | -132.0% | -165.1% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥1.79B | ¥1.73B | ¥1.33B | ¥2.06B | ¥1.21B |
| Total assets | ¥2.34B | ¥2.22B | ¥1.75B | ¥2.47B | ¥1.73B |
| Net assets | ¥1.89B | ¥1.79B | ¥1.16B | ¥1.92B | ¥1.12B |
| Share capital | ¥1.52B | ¥2.1B | ¥2.39B | ¥995.5M | ¥1.09B |
| Inventories | ¥59M | ¥71.5M | ¥64.1M | ¥46.2M | ¥49.4M |
| Property, plant and equipment | ¥4.2M | ¥2.4M | ¥1.2M | ¥0 | ¥36.3M |
| Current assets | ¥2.22B | ¥2.09B | ¥1.63B | ¥2.34B | ¥1.55B |
| Current liabilities | ¥392.5M | ¥370.5M | ¥539M | ¥493.4M | ¥374.9M |
| Short-term borrowings | ¥183M | ¥184M | ¥291M | ¥281.5M | ¥86.7M |
| Bonds | — | — | — | — | ¥175M |
| Total liabilities | ¥446.4M | ¥424.7M | ¥593.7M | ¥548.6M | ¥605.4M |
| Equity attributable to owners of parent | ¥1.86B | ¥1.78B | ¥1.14B | ¥1.91B | ¥1.11B |
| Retained earnings | -¥2.77B | -¥4.02B | -¥5.24B | -¥1.02B | -¥2B |
| Treasury stock | -¥292K | -¥292K | -¥292K | -¥292K | -¥292K |
EDINET (FSA Japan)
有価証券報告書－第22期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第20期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第18期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 41 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.